Thursday , October 28 2021

USFDA approves Glycopyrrolate ANDA filed from Indoco Remedies’ Goa Plant II


The United States Food & Drug Administration (USFDA) has approved Abbreviated New Drug Application (ANDA) for Glycopyrrolate Injection 0.2 mg/ml filed from Indoco Remedies’ Goa Plant II on behalf of its partner in the US. Glycopyrrolate is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions. The market size of this product in the US is $120 million.

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.

Please share this news
<div id="taboola-below-article-thumbnails"></div>
<script type="text/javascript">
  window._taboola = window._taboola || [];
    mode: 'thumbnails-a',
    container: 'taboola-below-article-thumbnails',
    placement: 'Below Article Thumbnails',
    target_type: 'mix'